171 related articles for article (PubMed ID: 36451394)
21. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.
Kayani I; Bomanji JB; Groves A; Conway G; Gacinovic S; Win T; Dickson J; Caplin M; Ell PJ
Cancer; 2008 Jun; 112(11):2447-55. PubMed ID: 18383518
[TBL] [Abstract][Full Text] [Related]
22. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
Sampathirao N; Basu S
J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
[TBL] [Abstract][Full Text] [Related]
23. Impact of 68Ga-DOTATOC PET/CT in comparison to 111In-Octreotide SPECT/CT in management of neuro-endocrine tumors: A case report.
Tolomeo A; Lopopolo G; Dimiccoli V; Perioli L; Modoni S; Scilimati A
Medicine (Baltimore); 2020 Feb; 99(7):e19162. PubMed ID: 32049844
[TBL] [Abstract][Full Text] [Related]
24. Functional imaging in differentiating bronchial masses: an initial experience with a combination of (18)F-FDG PET-CT scan and (68)Ga DOTA-TOC PET-CT scan.
Kumar A; Jindal T; Dutta R; Kumar R
Ann Nucl Med; 2009 Oct; 23(8):745-51. PubMed ID: 19784877
[TBL] [Abstract][Full Text] [Related]
25.
Parihar AS; Mittal BR; Kumar R; Shukla J; Bhattacharya A
Thyroid; 2020 Apr; 30(4):557-567. PubMed ID: 31870227
[No Abstract] [Full Text] [Related]
26. Altered biodistribution of [
van de Weijer T; Bemer F; de Vos-Geelen J; Hermans B; Mitea C; van der Pol JAJ; Lodewick T; Wildberger JE; Mottaghy FM
Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2420-2427. PubMed ID: 38403723
[TBL] [Abstract][Full Text] [Related]
27. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.
Gabriel M; Decristoforo C; Kendler D; Dobrozemsky G; Heute D; Uprimny C; Kovacs P; Von Guggenberg E; Bale R; Virgolini IJ
J Nucl Med; 2007 Apr; 48(4):508-18. PubMed ID: 17401086
[TBL] [Abstract][Full Text] [Related]
28. Biodistribution and first clinical results of
Ilhan H; Lindner S; Todica A; Cyran CC; Tiling R; Auernhammer CJ; Spitzweg C; Boeck S; Unterrainer M; Gildehaus FJ; Böning G; Jurkschat K; Wängler C; Wängler B; Schirrmacher R; Bartenstein P
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):870-880. PubMed ID: 31492994
[TBL] [Abstract][Full Text] [Related]
29. Detection of Bone Metastases by
Tian R; Xie Q; Yu F; Du C; Yao X; Zang S; Zhang C; Zhang P; Shao G; Yang Z; Wang F; Yu J
Contrast Media Mol Imaging; 2022; 2022():1750132. PubMed ID: 36447752
[TBL] [Abstract][Full Text] [Related]
30. ⁶⁸Ga-DOTA-TOC-PET/CT detects heart metastases from ileal neuroendocrine tumors.
Calissendorff J; Sundin A; Falhammar H
Endocrine; 2014 Sep; 47(1):169-76. PubMed ID: 24272595
[TBL] [Abstract][Full Text] [Related]
31. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
32. Head-to-Head Comparison of
Zhu W; Cheng Y; Wang X; Yao S; Bai C; Zhao H; Jia R; Xu J; Huo L
J Nucl Med; 2020 Jun; 61(6):897-903. PubMed ID: 31676731
[No Abstract] [Full Text] [Related]
33. Dual-tracer PET/CT imaging to determine tumor heterogeneity in a patient with metastatic ACTH-secreting neuroendocrine neoplasm: A case report and literature review.
Ryzhkova D; Mitrofanova L; Tsoy U; Grineva E; Schlyakhto E
Front Endocrinol (Lausanne); 2022; 13():958442. PubMed ID: 36133304
[TBL] [Abstract][Full Text] [Related]
34. The role of 68Ga-DOTA-NOC PET/CT in evaluating neuroendocrine tumors: real-world experience from two large neuroendocrine tumor centers.
Haidar M; Shamseddine A; Panagiotidis E; Jreige M; Mukherji D; Assi R; Abousaid R; Ibrahim T; Haddad MM; Vinjamuri S
Nucl Med Commun; 2017 Feb; 38(2):170-177. PubMed ID: 27922538
[TBL] [Abstract][Full Text] [Related]
35. (68)Ga-DOTA-peptide: A novel molecular biomarker for nasopharyngeal carcinoma.
Khor LK; Loi HY; Sinha AK; Tong KT; Goh BC; Loh KS; Lu SJ
Head Neck; 2016 Apr; 38(4):E76-80. PubMed ID: 26275126
[TBL] [Abstract][Full Text] [Related]
36. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT.
Kroiss A; Putzer D; Decristoforo C; Uprimny C; Warwitz B; Nilica B; Gabriel M; Kendler D; Waitz D; Widmann G; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):514-23. PubMed ID: 23291643
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the application of 18F-FDG and 68Ga-DOTATATE PET/CT in neuroendocrine tumors: A retrospective study.
Hu X; Li D; Wang R; Wang P; Cai J
Medicine (Baltimore); 2023 May; 102(19):e33726. PubMed ID: 37171344
[TBL] [Abstract][Full Text] [Related]
38. Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET/CT on the basis of volumetric parameters in neuroendocrine tumors.
Abdulrezzak U; Kurt YK; Kula M; Tutus A
Nucl Med Commun; 2016 Aug; 37(8):874-81. PubMed ID: 27096719
[TBL] [Abstract][Full Text] [Related]
39. The added value of
Kazmierczak PM; Rominger A; Wenter V; Spitzweg C; Auernhammer C; Angele MK; Rist C; Cyran CC
Eur Radiol; 2017 Apr; 27(4):1676-1684. PubMed ID: 27436022
[TBL] [Abstract][Full Text] [Related]
40.
Kroiss AS; Uprimny C; Shulkin BL; Gruber L; Frech A; Url C; Riechelmann H; Sprinzl GM; Thomé C; Treglia G; Kjaer A; Fraedrich G; Virgolini IJ
Nucl Med Biol; 2019 Apr; 71():47-53. PubMed ID: 31152973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
